ITF Pharma has announced that Tiglutik (riluzole) oral liquid suspension is available in the US for the treatment of amyotrophic lateral sclerosis (ALS).
Tiglutik is supplied as a thickened riluzole liquid that is intended to ease administration for patients with dysphagia. It was approved by the Food and Drug Administration (FDA) in September 2018 based on results from bioavailability studies which compared riluzole tablets to Tiglutik.
“The availability of Tiglutik […] will allow continued ease of administration when a patient can no longer swallow the pills. This will enable people living with ALS to continue to take riluzole throughout the course of their illness and minimizes the difficulties and time related to crushing pills into liquid,” said Terry Heiman-Patterson, MD, director, Center for Neurodegenerative Disorders, professor, Lewis Katz School of Medicine at Temple University in Philadelphia.
Tiglutik is available as a 50mg/10mL strength oral suspension in 300mL bottles in 2-count cartons with supplies.
For more information visit ITFpharma.com.
This article originally appeared on MPR